462 related articles for article (PubMed ID: 16322301)
1. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
Buchholz TA; Garg AK; Chakravarti N; Aggarwal BB; Esteva FJ; Kuerer HM; Singletary SE; Hortobagyi GN; Pusztai L; Cristofanilli M; Sahin AA
Clin Cancer Res; 2005 Dec; 11(23):8398-402. PubMed ID: 16322301
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy.
Buchholz TA; Tu X; Ang KK; Esteva FJ; Kuerer HM; Pusztai L; Cristofanilli M; Singletary SE; Hortobagyi GN; Sahin AA
Cancer; 2005 Aug; 104(4):676-81. PubMed ID: 15981280
[TBL] [Abstract][Full Text] [Related]
3. NF-kappaB activation through the alternative pathway correlates with chemoresistance and poor survival in extranodal NK/T-cell lymphoma, nasal type.
Liu X; Wang B; Ma X; Guo Y
Jpn J Clin Oncol; 2009 Jul; 39(7):418-24. PubMed ID: 19395464
[TBL] [Abstract][Full Text] [Related]
4. Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients.
Montagut C; Tusquets I; Ferrer B; Corominas JM; Bellosillo B; Campas C; Suarez M; Fabregat X; Campo E; Gascon P; Serrano S; Fernandez PL; Rovira A; Albanell J
Endocr Relat Cancer; 2006 Jun; 13(2):607-16. PubMed ID: 16728586
[TBL] [Abstract][Full Text] [Related]
5. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?
Kymionis GD; Dimitrakakis CE; Konstadoulakis MM; Arzimanoglou I; Leandros E; Chalkiadakis G; Keramopoulos A; Michalas S
J Surg Res; 2001 Aug; 99(2):161-8. PubMed ID: 11469882
[TBL] [Abstract][Full Text] [Related]
6. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma.
Krajewski S; Blomqvist C; Franssila K; Krajewska M; Wasenius VM; Niskanen E; Nordling S; Reed JC
Cancer Res; 1995 Oct; 55(19):4471-8. PubMed ID: 7671262
[TBL] [Abstract][Full Text] [Related]
7. The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer.
Sjöström J; Blomqvist C; von Boguslawski K; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Wist E; Valvere V; Takayama S; Reed JC; Saksela E
Clin Cancer Res; 2002 Mar; 8(3):811-6. PubMed ID: 11895913
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
9. Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy.
Parton M; Krajewski S; Smith I; Krajewska M; Archer C; Naito M; Ahern R; Reed J; Dowsett M
Clin Cancer Res; 2002 Jul; 8(7):2100-8. PubMed ID: 12114409
[TBL] [Abstract][Full Text] [Related]
10. Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma.
Zhang F; Yang Y; Smith T; Kau SW; McConathy JM; Esteva FJ; Kuerer HM; Symmans WF; Buzdar AU; Hortobagyi GN; Pusztai L
Cancer; 2003 Apr; 97(7):1758-65. PubMed ID: 12655533
[TBL] [Abstract][Full Text] [Related]
11. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
[TBL] [Abstract][Full Text] [Related]
12. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
13. Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients.
Kariya S; Ogawa Y; Nishioka A; Moriki T; Ohnishi T; Ito S; Murata Y; Yoshida S
Radiat Med; 2005 May; 23(3):189-94. PubMed ID: 15940066
[TBL] [Abstract][Full Text] [Related]
14. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response.
Rajan R; Poniecka A; Smith TL; Yang Y; Frye D; Pusztai L; Fiterman DJ; Gal-Gombos E; Whitman G; Rouzier R; Green M; Kuerer H; Buzdar AU; Hortobagyi GN; Symmans WF
Cancer; 2004 Apr; 100(7):1365-73. PubMed ID: 15042669
[TBL] [Abstract][Full Text] [Related]
15. Id-1 regulates Bcl-2 and Bax expression through p53 and NF-kappaB in MCF-7 breast cancer cells.
Kim H; Chung H; Kim HJ; Lee JY; Oh MY; Kim Y; Kong G
Breast Cancer Res Treat; 2008 Nov; 112(2):287-96. PubMed ID: 18158619
[TBL] [Abstract][Full Text] [Related]
16. Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation.
Trask DK; Wolf GT; Bradford CR; Fisher SG; Devaney K; Johnson M; Singleton T; Wicha M
Laryngoscope; 2002 Apr; 112(4):638-44. PubMed ID: 12150516
[TBL] [Abstract][Full Text] [Related]
17. The effect of chemotherapy on Ki-67, Bcl-2 and Bak expression in primary tumors and lymph node metastases of breast cancer.
Koda M; Sulkowska M; Kanczuga-Koda L; Tomaszewski J; Kucharczuk W; Lesniewicz T; Cymek S; Sulkowski S
Oncol Rep; 2007 Jul; 18(1):113-9. PubMed ID: 17549355
[TBL] [Abstract][Full Text] [Related]
18. Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients.
Martínez-Arribas F; Núñez-Villar MJ; Lucas AR; Sánchez J; Tejerina A; Schneider J
Anticancer Res; 2003; 23(1B):565-8. PubMed ID: 12680147
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy.
Yang Q; Sakurai T; Yoshimura G; Suzuma T; Umemura T; Nakamura M; Nakamura Y; Mori I; Kakudo K
Oncol Rep; 2003; 10(1):121-5. PubMed ID: 12469156
[TBL] [Abstract][Full Text] [Related]
20. Is drug-induced toxicity a good predictor of response to neo-adjuvant chemotherapy in patients with breast cancer?--a prospective clinical study.
Chintamani ; Singhal V; Singh JP; Lyall A; Saxena S; Bansal A
BMC Cancer; 2004 Aug; 4():48. PubMed ID: 15310398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
